Develops a pill-based technology for the oral delivery of biologics, aiming to replace injections.
Rani Therapeutics Holdings, Inc. is a pioneering clinical-stage biotherapeutics company focused on revolutionizing drug delivery through its innovative RaniPill capsule platform. This platform aims to transform the way biologics are administered by enabling oral dosing, thereby potentially replacing traditional subcutaneous or IV injections. By leveraging this technology, Rani Therapeutics seeks to enhance patient convenience and compliance while maintaining therapeutic efficacy.
The company's diverse product pipeline underscores its commitment to addressing a range of medical conditions with unmet needs. Among its promising developments are RT-101, an octreotide currently in Phase I clinical trials for neuroendocrine tumors and acromegaly, and RT-105, an anti-TNF-alpha antibody targeted at treating psoriatic arthritis. Additionally, Rani Therapeutics is advancing RT-102, a parathyroid hormone, through preclinical studies for osteoporosis treatment, alongside RT-109 for growth hormone deficiency and RT-110 for hypoparathyroidism. Furthermore, RT-106, a basal insulin designed for type 2 diabetes management, represents another significant milestone in the company's robust pipeline.
Founded in 2012 and headquartered in San Jose, California, Rani Therapeutics continues to push boundaries in biopharmaceutical innovation. With a dedication to pioneering oral biologics delivery systems, the company stands poised to reshape therapeutic landscapes and improve patient outcomes across various chronic and complex diseases.